ArticleNature communications2026
Evaluating single-cell ATAC-seq atlasing technologies using sequence-to-function modeling.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating single-cell ATAC-seq atlasing technologies using sequence-to-function modeling.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Deciphering the cis-regulatory logic underlying cell type identity remains a key challenge in biology. Single-cell chromatin accessibility (scATAC-seq) atlases enable training of sequence-to-function (S2F) deep learning models to decode enhancer logic. Yet, optimal criteria for constructing training datasets, i.e., the number of cells and ATAC fragments, remain unclear. Moreover, the suitability of different scATAC-seq platforms for such models has not been systematically tested. We introduce HyDrop v2, an improved custom droplet scATAC-seq method, and perform the first benchmark of scATAC-seq platforms focusing on its capacity to train S2F models and its capacity to yield TF footprints in different species. We show that lower fragment counts can be compensated for by increased cell numbers. S2F models trained on custom or commercial data perform comparably in enhancer prediction, sequence explainability, and transcription factor footprinting. We demonstrate that integrating data from different scATAC-seq platforms enables large-scale, cost-efficient atlas construction for deep learning-based regulatory modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.